Therapeutic Divergence in 5-HT2A Agonism: Psilocybin and Phenalkylamines for Demoralization Syndrome
ACS Medicinal Chemistry Letters August 15, 2025 DOI: 10.1021/acsmedchemlett.5c00475 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Keywords | Agonism Hallucinogen Divergence linguistics 5-HT Receptor Psychotherapist Pharmacology |
| Key findings | Structural modifications of phenalkylamines and tryptamines can yield functional selectivity at 5-HT receptors, reducing hallucinogenic risk while preserving therapeutic efficacy for demoralization syndrome and depression-related conditions. |
Abstract
Novel phenalkylamines and tryptamines such as psilocybin demonstrate promising nontraditional pharmacological profiles for treating psychiatric syndromes. Structural modifications yield functional selectivity at 5-HT receptors, mitigating hallucinogenic risk while preserving therapeutic efficacy. This study integrates receptor and behavioral data to support phenalkylamines and psilocybin as rational therapeutics for demoralization syndrome and depression-related conditions.